Symetis develops minimally-invasive transcatheter aortic valve implantation devices for patients with severe heart disease.
The company’s heart devices are “strongly complementary to our cornerstone Lotus valve platform, and this compelling combination of technologies will allow us to provide interventional cardiologists and cardiac surgeons with multiple TAVI offerings for varying patient pathologies and anatomy,” Ian Meredith, MD, executive vice president and global CMO of Boston Scientific, said in a statement.
The deal is expected to close in the second quarter of 2017.
More articles on supply chain:
How SSM Health’s pharmacy concierge program helps patients manage high drug costs
Viewpoint: US should strengthen existing laws to lower drug prices — not make new ones
Mexico border tax could lead to medical device shortages: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
